Sorafenib in advanced, heavily pretreated patients with soft tissue sarcomas

被引:7
作者
Braemswig, Kira [1 ]
Ploner, Ferdinand [4 ]
Martel, Alexandra [1 ]
Bauernhofer, Thomas [4 ]
Hilbe, Wolfgang [5 ]
Kuehr, Thomas [6 ]
Leitgeb, Clemens [2 ]
Mlineritsch, Brigitte [7 ]
Petzer, Andreas [8 ]
Seebacher, Veronika [3 ]
Stoeger, Herbert [4 ]
Girschikofsky, Michael [9 ]
Hochreiner, Gerhard [10 ]
Ressler, Sigrun [7 ]
Romeder, Franz [7 ]
Woell, Ewald [11 ]
Brodowicz, Thomas [1 ]
机构
[1] Med Univ Vienna, Dept Internal Med 1, Div Oncol, Ctr Comprehens Canc, A-1090 Vienna, Austria
[2] Wilhelminenspital Stadt Wien, Dept Med & Med Oncol 1, Vienna, Austria
[3] Med Univ Vienna, Dept Gynecol, A-1090 Vienna, Austria
[4] Med Univ Graz, Div Oncol, Dept Internal Med, Graz, Austria
[5] Med Univ Innsbruck, Dept Internal Med, A-6020 Innsbruck, Austria
[6] Hosp Wels Grieskirchen, Dept Haematol & Oncol, Wels, Austria
[7] Paracelsus Med Univ Salzburg, Med Dept Haematol Med Oncol Haemostaseol Rheumato, Salzburg, Austria
[8] Hosp Barmherzige Schwestern Linz, Dept Med Oncol Haematol & Gastroenterol, Linz, Austria
[9] Elisabethinen Hosp Linz, Linz, Austria
[10] Gen Hosp Linz, Dept Internal Med 3, Ctr Med Oncol & Haematol, Linz, Austria
[11] St Vincent Hosp Zams, Dept Internal Med, Zams, Austria
关键词
chemotherapy; leiomyosarcoma; sarcoma; sorafenib; PHASE-II TRIAL; WEEKLY PACLITAXEL; SYSTEMIC THERAPY; LEIOMYOSARCOMA; ANGIOSARCOMA; TRABECTEDIN; CHEMOTHERAPY; STRATEGIES; RECURRENT; SURVIVAL;
D O I
10.1097/CAD.0000000000000108
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Therapeutic options for patients with advanced pretreated soft tissue sarcomas are limited. However, in this setting, sorafenib has shown promising results. We reviewed the data of 33 patients with soft tissue sarcoma treated with sorafenib within a named patient program in Austria. Twelve physicians from eight different hospitals provided records for the analysis of data. Among the 33 patients, the predominant histological subtype of sarcoma was leiomyosarcoma (n = 18, 55%). Other subtypes were represented by only one or two cases. Fifteen patients presented with metastases at the time of diagnosis. Another 17 patients developed metastases later in the course of the disease (data on one patient are missing). Most of the 33 patients had undergone resection of the primary (n = 29, 88%) and half of the patients had received radiotherapy (n = 17, 52%). Chemotherapy for metastatic disease had been administered to 30 patients (91%). The majority had received two or more regimens of chemotherapy (n = 25, 76%) before sorafenib treatment. The use of sorafenib resulted in a median time to treatment failure of 92 days in patients with leiomyosarcoma and 45 days in patients with other histological subtypes. One-third of the patients derived benefits from treatment: four patients were documented with partial response and six with stabilized disease. In terms of treatment-related toxicity, skin problems of various degrees and gastrointestinal disturbances were frequently reported. In this retrospective analysis of heavily pretreated patients with advanced soft tissue sarcomas, sorafenib was associated with some antitumor activity and an acceptable toxicity profile. Anti-Cancer Drugs 25:848-853 (C) 2014 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:848 / 853
页数:6
相关论文
共 50 条
[21]   IFOSFAMIDE AND ETOPOSIDE IN THE TREATMENT OF ADVANCED SOFT-TISSUE SARCOMAS [J].
BLAIR, SC ;
ZALUPSKI, MM ;
BAKER, LH .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1994, 17 (06) :480-484
[22]   Neoadjuvant and adjuvant chemotherapy of localized advanced soft tissue sarcomas [J].
Hartmann, J. T. ;
Schuette, J. .
ONKOLOGE, 2009, 15 (04) :389-+
[23]   Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy [J].
Ray-Coquard, I. ;
Rizzo, E. ;
Blay, J. Y. ;
Casali, P. ;
Judson, I. ;
Hansen, A. Krarup ;
Lindner, L. H. ;
dei Tos, A. P. ;
Gelderblom, H. ;
Marreaud, S. ;
Litiere, S. ;
Rutkowski, P. ;
Hohenberger, P. ;
Gronchi, A. ;
van der Graaf, W. T. .
GYNECOLOGIC ONCOLOGY, 2016, 142 (01) :95-101
[24]   Activity of regorafenib in advanced pretreated soft tissue sarcoma Results of a single-center phase II study [J].
Marrari, Andrea ;
Bertuzzi, Alexia ;
Bozzarelli, Silvia ;
Gennaro, Nicolo ;
Giordano, Laura ;
Quagliuolo, Vittorio ;
De Sanctis, Rita ;
Sala, Simona ;
Balzarini, Luca ;
Santoro, Armando .
MEDICINE, 2020, 99 (26) :E20719
[25]   Clinical Outcome of the Patients With Brain Metastasis from Soft Tissue Sarcomas [J].
Takemori, Toshiyuki ;
Kawamoto, Teruya ;
Morishita, Masayuki ;
Hara, Hitomi ;
Fukase, Naomasa ;
Kawakami, Yohei ;
Fujiwara, Shuichi ;
Kitayama, Kazumichi ;
Yahiro, Shunsuke ;
Miyamoto, Tomohiro ;
Fujimoto, Takuya ;
Fujita, Ikuo ;
Mifune, Yutaka ;
Hoshino, Yuichi ;
Kakutani, Kenichiro ;
Matsumoto, Tomoyuki ;
Matsushita, Takehiko ;
Niikura, Takahiro ;
Kuroda, Ryosuke ;
Akisue, Toshihiro .
ANTICANCER RESEARCH, 2021, 41 (02) :1027-1034
[26]   Doxorubicin and trabectedin in leiomyosarcoma: pioneering a new era of smart combinations in soft tissue sarcomas [J].
Assi, Tarek ;
Le Cesne, Axel .
FUTURE ONCOLOGY, 2025,
[27]   Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens [J].
Blay, JY ;
Judson, I ;
Rodenhuis, S ;
Hermans, C ;
Smith, M ;
van Glabbeke, M ;
Verweij, J .
ANTI-CANCER DRUGS, 1999, 10 (10) :873-877
[28]   Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas [J].
von Mehren, Margaret ;
Rankin, Cathryn ;
Goldblum, John R. ;
Demetri, George D. ;
Bramwell, Vivien ;
Ryan, Christopher W. ;
Borden, Ernest .
CANCER, 2012, 118 (03) :770-776
[29]   Gemcitabine in advanced adult soft-tissue sarcomas.: A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group [J].
Svancárová, L ;
Blay, JY ;
Judson, IR ;
van Hoesel, QGCM ;
van Oosterom, AT ;
le Cesne, A ;
Keizer, HJ ;
Hermans, C ;
van Glabbeke, M ;
Verweij, J ;
Hogendoorn, PCW ;
Nielsen, OS .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (04) :556-559
[30]   The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas [J].
Tascilar, Metin ;
Loos, Walter J. ;
Seynaeve, Caroline ;
Verweij, Jaap ;
Sleijfer, Stefan .
ONCOLOGIST, 2007, 12 (11) :1351-1360